Deals this week: Repligen, Pharmacosmos, Orig3n


Bioprocessing company Repligen intends to raise gross proceeds of approximately $120m through an underwritten public offering of shares of its common stock.

The company has also granted underwriters an option to buy additional shares within 30 days at offer price less underwriting discounts and commissions.

The proceeds will be used to fund working capital, possible acquisitions, or investments in other business segments.

"The financing will be used to advance its product development for Huntington's disease and expand its therapeutic pipeline to treat additional neurodegenerative disorders."

Healthcare solution provider Pharmacosmos has agreed to grant exclusive commercialisation rights of its intravenous iron replacement therapy Manover to pharmaceutical firm Laboratoire Aguettant, which is based in France.

The move enables France-based commercialisation of the therapy, which is used for the treatment of iron deficiency anaemia (IDA).

In a move to strengthen its research efforts in developing cell therapies, biotechnology firm Orig3n has closed a $20m venture financing round led by Hatteras Venture Partners.

The round has also seen the participation of Spectrum Health Ventures, Laboratory Corp of America Holdings, Syno Capital, Ktb-Korus Fund, MGC Venture Partners 2013, L.P., DEFTA Partners, and 180 Degree Capital (Harris & Harris Group, Inc.).

Biopharmaceutical company Mitoconix Bio has raised $20m in a Series A financing round led by Remiges Ventures.

The financing will be used to advance its product development for Huntington's disease and expand its therapeutic pipeline to treat additional neurodegenerative disorders.

Neos Therapeutics intends to raise gross proceeds of $32.4m through a public offering of 4.8 million shares of its common stock.

It has also granted a 30-day option to underwriters to buy additional shares of common stock worth up to $4.9m.

The proceeds will be used to support the ongoing commercialisation of Adzenys XR-ODT, launch Cotempla XR-ODT, and for other general corporate purposes.